GO:0031283 negative regulation of guanylate cyclase activity: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031283 describes any process that stops, prevents, or reduces the frequency, rate or extent of guanylate cyclase activity, thereby lowering cyclic GMP (cGMP) production.
• The best-characterized example is the calcium-dependent negative feedback control of retinal membrane guanylyl cyclase (RetGC) by GCAP proteins and the RD3 protein.
• Guanylate cyclase activity is also modulated indirectly through protein-protein interactions that regulate nitric oxide synthase and downstream cGMP signaling.
• Dysregulation of guanylate cyclase negative regulation is linked to retinal dystrophies, vascular tone disorders, and inflammatory skin diseases.
• Key experimental approaches include knockout and point-mutation cell models, cGMP quantification, and CRISPR library screening to identify novel negative regulators.
• EDITGENE provides knockout, point-mutation, knock-in, overexpression cell models and CRISPR library screening to dissect GO:0031283-related pathways.
Description
Guanylate cyclases are enzymes that synthesize cyclic GMP (cGMP), a second messenger controlling vision, vascular tone, and many other physiological processes. The Gene Ontology term GO:0031283, negative regulation of guanylate cyclase activity, captures the diverse cellular mechanisms that restrain this enzymatic activity, preventing excessive cGMP accumulation. Understanding these brakes on cGMP production is essential because loss of negative regulation can drive retinal degeneration, hypertension, and inflammatory pathology. This article integrates the QuickGO definition with verified PubMed literature to explain the molecular players, disease relevance, and research methods for studying GO:0031283.
negative regulation of guanylate cyclase activity At A Glance
| GO ID | GO:0031283 |
|---|---|
| GO term | negative regulation of guanylate cyclase activity |
| Ontology | biological_process |
| Synonym | inhibition of guanylate cyclase activity; downregulation of guanylate cyclase activity |
| Major function | Reduces cGMP synthesis by inhibiting guanylate cyclase enzymes |
| Key regulators | GCAP proteins, RD3, calcium ions, eNOS-interacting proteins |
| Physiological context | Phototransduction, vascular tone, inflammation |
| Disease links | Retinal dystrophy, hypertension, CARD14-associated psoriasis |
What Is GO:0031283?
According to QuickGO, GO:0031283 (negative regulation of guanylate cyclase activity) is any biological process that stops, prevents, or reduces the frequency, rate or extent of guanylate cyclase activity. In practice, this means the cell lowers the production of cGMP by inhibiting the enzyme guanylate cyclase, either through direct protein-protein interactions, calcium-dependent feedback, or other regulatory inputs.
Why Is negative regulation of guanylate cyclase activity Important in Cell Biology?
Negative regulation of guanylate cyclase activity is critical for preventing excessive cGMP signaling, which can be toxic to photoreceptors and disruptive to vascular homeostasis. In the retina, the RD3 protein and GCAPs mediate calcium-dependent feedback that shuts down RetGC under bright light, protecting rods and cones from degeneration. In the vasculature, modulation of guanylate cyclase activity influences renal preglomerular tone and blood pressure. Moreover, inflammatory signaling through CARD14 and mTORC1 intersects with cGMP pathways, highlighting broader roles in skin disease. Thus, GO:0031283 is a nexus for understanding both normal physiology and multiple human disorders.
• Prevents cGMP toxicity in photoreceptors by shutting down RetGC in bright light.
• Maintains vascular tone and blood pressure through regulated cGMP production.
• Mutations in GCAP2 (G157R) impair negative regulation and cause retinal dystrophy.
• RD3 mutations lead to Leber congenital amaurosis by disrupting RetGC inhibition.
• CARD14 signalosome and mTORC1 crosstalk link guanylate cyclase regulation to psoriasis.
• eNOS-interacting proteins modulate cGMP synthesis in endothelial cells.
• Provides targets for therapeutic intervention in hypertension and retinopathies.
• Essential for interpreting CRISPR screens aimed at cGMP signaling components.
What Happens During negative regulation of guanylate cyclase activity?
Calcium-dependent feedback inhibition of RetGC
In simple terms: When calcium levels drop in a light-exposed photoreceptor, proteins called GCAPs change shape and stop the enzyme that makes cGMP.
In retinal rod and cone outer segments, the membrane guanylyl cyclase RetGC is inhibited by guanylate cyclase-activating proteins (GCAPs) in a calcium-dependent manner. Under low calcium (bright light), GCAPs bind to RetGC and reduce its catalytic activity, lowering cGMP and closing cyclic nucleotide-gated channels. This negative feedback is essential for light adaptation and photoreceptor survival.
Role of RD3 protein in RetGC repression
In simple terms: RD3 acts like a brake that keeps RetGC turned down when it is not needed.
The RD3 protein binds to RetGC and stabilizes its inactive state, contributing to negative regulation of guanylate cyclase activity. Loss of RD3 function leads to unchecked RetGC activity and retinal degeneration, as seen in Leber congenital amaurosis. RD3 therefore is a key component of the negative regulation machinery for RetGC.
Protein-protein interactions modulating guanylate cyclase
In simple terms: Other proteins can grab onto guanylate cyclase or its partners and put the brakes on cGMP production.
Beyond calcium feedback, guanylate cyclase activity can be negatively regulated through protein-protein interactions. For example, endothelial nitric oxide synthase (eNOS) interacts with partner proteins that modulate its activity, indirectly affecting cGMP synthesis by soluble guanylate cyclase. Such interactions provide additional layers of negative control in vascular and other tissues.
Crosstalk with inflammatory and mTORC1 signaling
In simple terms: Inflammatory signals can change how cells handle cGMP by moving proteins around inside the cell.
CARD14 signalosome formation is associated with endosomal relocation and mTORC1-induced keratinocyte proliferation, processes that intersect with cGMP-related signaling. This crosstalk suggests that negative regulation of guanylate cyclase activity may be integrated into broader inflammatory and growth factor pathways.
Key Genes Involved in GO:0031283 negative regulation of guanylate cyclase activity
The following genes and proteins are experimentally implicated in negative regulation of guanylate cyclase activity or its downstream cGMP signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GUCA1A | Encodes GCAP1, calcium sensor that inhibits RetGC | Mutations cause cone-rod dystrophy; target for point-mutation studies |
| GUCA1B | Encodes GCAP2, calcium-dependent regulator of RetGC | G157R variant linked to retinal dystrophy; used in knock-in models |
| RD3 | Binds RetGC and maintains inactive state | Loss causes Leber congenital amaurosis; knockout models available |
| GUCY2D | Encodes RetGC1, the target of negative regulation | Mutations cause retinal dystrophy; key for overexpression studies |
| GUCY2F | Encodes RetGC2, another retinal guanylyl cyclase | Less studied but relevant for combinatorial knockout |
| NOS3 | Encodes eNOS, modulates soluble guanylate cyclase via NO | Protein interactions affect cGMP; target for KO in endothelial cells |
| CARD14 | Scaffold in psoriasis, links to mTORC1 and endosomal traffic | Mutations cause psoriasis; used in signalosome studies |
| MTOR | Kinase integrating growth and inflammatory signals | mTORC1 inhibition alters CARD14 localization; relevant to cGMP crosstalk |
| CALM1 | Calmodulin, calcium sensor modulating eNOS and GCs | Potential indirect regulator; used in point-mutation studies |
| HSP90 | Chaperone for eNOS and guanylate cyclases | Protein-protein interaction studies |
| AKT1 | Kinase downstream of mTORC1 | Phosphorylation may affect guanylate cyclase regulators |
| PRKAA1 | AMPK, energy sensor | Potential crosstalk with cGMP pathways |
| STAT3 | Transcription factor in inflammation | Modulated by CARD14 signaling; links to cGMP |
| NFKB1 | Inflammatory transcription factor | Downstream of CARD14; may influence guanylate cyclase expression |
| VEGFA | Angiogenic factor regulated by cGMP | Vascular tone studies; target for KO |
| EDN1 | Endothelin-1, vasoconstrictor | Modulates renal vascular tone via cGMP |
| CALD1 | Caldesmon, actin-binding protein | Regulates vascular tone in preglomerular renal vasculature |
| GUCY1A1 | Soluble guanylate cyclase subunit | Target of negative regulation in vascular cells |
How Is negative regulation of guanylate cyclase activity Regulated?
Negative regulation of guanylate cyclase activity is itself regulated by calcium levels, protein-protein interactions, and inflammatory signaling. In photoreceptors, calcium-bound GCAPs and RD3 directly inhibit RetGC. In endothelial cells, eNOS-interacting proteins modulate NO production, which in turn affects soluble guanylate cyclase activity. Inflammatory pathways involving CARD14 and mTORC1 can alter the localization of signaling components, indirectly influencing cGMP synthesis. Additionally, heme availability affects soluble guanylate cyclase maturation and activity, as heme is a required cofactor.
negative regulation of guanylate cyclase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GUCY2D | Retinal dystrophy, Leber congenital amaurosis | Knockout and point-mutation iPSC-derived photoreceptors |
| GUCA1B | Retinal dystrophy (G157R variant) | Knock-in mice or cell lines expressing G157R |
| RD3 | Leber congenital amaurosis | RD3 knockout retinal organoids |
| CARD14 | Psoriasis, inflammatory skin disease | CARD14 overexpression in keratinocytes |
| NOS3 | Hypertension, endothelial dysfunction | eNOS knockout endothelial cells |
Retinal dystrophies and Leber congenital amaurosis
Mutations in GUCY2D, GUCA1A, GUCA1B, and RD3 disrupt the negative regulation of RetGC, leading to abnormal cGMP accumulation and photoreceptor death. The G157R variant of GCAP2 impairs calcium-dependent inhibition, causing retinal dystrophy. RD3 mutations abolish RetGC repression, resulting in Leber congenital amaurosis.
Hypertension and vascular tone disorders
Guanylate cyclase activity in vascular smooth muscle regulates blood pressure. Negative regulation of this activity by eNOS-interacting proteins and caldesmon affects preglomerular renal vascular tone. Dysregulation can contribute to hypertension and renal disease.
Inflammatory skin diseases
CARD14 signalosome formation and mTORC1-induced keratinocyte proliferation are associated with psoriasis. This pathway intersects with cGMP signaling, suggesting that negative regulation of guanylate cyclase activity may modulate inflammatory skin disease.
From negative regulation of guanylate cyclase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of RD3 increase RetGC activity? | RD3 knockout cell line or retinal organoid |
| Does the GCAP2 G157R mutation impair calcium-dependent inhibition? | Point-mutation knock-in of GUCA1B G157R |
| Can overexpression of GCAP1 reduce cGMP in photoreceptors? | Overexpression cell model with GUCA1A |
| How does CARD14 signalosome affect cGMP? | CARD14 tagged knock-in for live imaging |
| What proteins interact with eNOS to modulate cGMP? | Proteomics with eNOS knockout background |
| Which genes negatively regulate guanylate cyclase in a genome-wide screen? | CRISPR library screening in cGMP reporter cells |
How to Study the negative regulation of guanylate cyclase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| cGMP ELISA | Intracellular cGMP concentration | Quantifying negative regulation in cell lines |
| Live-cell cGMP biosensor imaging | Real-time cGMP dynamics | Photoreceptor and vascular studies |
| Co-immunoprecipitation | Protein-protein interactions | Identifying RD3-RetGC or eNOS complexes |
| CRISPR knockout screening | Gene requirement for cGMP levels | Discovery of novel negative regulators |
| RNA-seq | Transcriptional changes | Pathway analysis after gene knockout |
| Phosphoproteomics | Kinase signaling changes | mTORC1 and CARD14 crosstalk |
| Calcium imaging | Intracellular calcium dynamics | GCAP-mediated feedback in retina |
cGMP quantification assays
Direct measurement of cyclic GMP levels using ELISA or mass spectrometry is the gold standard to assess negative regulation of guanylate cyclase activity. These assays can be applied to cell lysates or live cells expressing cGMP biosensors.
Calcium imaging and phototransduction assays
In retinal models, calcium imaging and patch-clamp recordings of cyclic nucleotide-gated channels reveal how calcium feedback inhibits RetGC. These methods are essential for studying GCAP and RD3 function.
Protein-protein interaction studies
Co-immunoprecipitation, proximity ligation, and mass spectrometry identify interactions between guanylate cyclases and their negative regulators, such as eNOS-interacting proteins and RD3.
CRISPR screening and bioinformatics
Genome-wide CRISPR knockout libraries coupled with cGMP reporters can uncover novel negative regulators. Bioinformatics analysis of screen hits identifies enriched pathways and potential drug targets.
How CRISPR Can Be Used to Study GO:0031283 negative regulation of guanylate cyclase activity
Knockout
CRISPR knockout of RD3, GUCA1A, or GUCA1B in retinal cell lines or organoids abolishes negative regulation, leading to elevated cGMP and photoreceptor degeneration phenotypes. These models are used to validate gene function in GO:0031283.
Point Mutation
Introducing the GCAP2 G157R point mutation via CRISPR base editing or HDR recreates a human retinal dystrophy allele, allowing precise study of impaired calcium-dependent inhibition of RetGC.
Knock-in
Tagged knock-in of CARD14 or RD3 with fluorescent or affinity tags enables live imaging and interactome studies to dissect their role in negative regulation of guanylate cyclase activity.
Overexpression
Overexpression of GCAP1 or RD3 in cell models can suppress guanylate cyclase activity, providing a gain-of-function system to test negative regulation and potential therapeutics.
How EDITGENE Supports negative regulation of guanylate cyclase activity Research
Researchers studying negative regulation of guanylate cyclase activity-related genes often need to determine whether a candidate gene is causally involved in cGMP suppression or whether it is merely a bystander. EDITGENE provides the CRISPR tools and cell models to answer these questions with rigor.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of guanylate cyclase activity research.
Frequently Asked Questions About negative regulation of guanylate cyclase activity
What is negative regulation of guanylate cyclase activity?
It is any process that reduces the frequency, rate, or extent of guanylate cyclase activity, thereby lowering cGMP production, as defined by GO:0031283.
What genes are involved in negative regulation of guanylate cyclase activity?
Key genes include RD3, GUCA1A, GUCA1B, GUCY2D, NOS3, and CARD14, which encode proteins that directly or indirectly inhibit guanylate cyclase.
How does calcium regulate guanylate cyclase activity?
In photoreceptors, calcium-bound GCAP proteins bind to RetGC and inhibit its activity, a classic example of negative regulation.
What diseases are linked to defective negative regulation of guanylate cyclase?
Retinal dystrophies such as Leber congenital amaurosis, hypertension, and inflammatory skin diseases like psoriasis.
What is the role of RD3 in guanylate cyclase regulation?
RD3 binds RetGC and maintains it in an inactive state; loss of RD3 causes unchecked cGMP production and retinal degeneration.
How can I study negative regulation of guanylate cyclase activity in the lab?
Use cGMP ELISA, live-cell biosensors, CRISPR knockout of candidate genes, and co-immunoprecipitation to assess regulation.
What CRISPR models are available for GO:0031283 research?
Knockout, point-mutation, knock-in, and overexpression cell models, as well as CRISPR library screening, are available from EDITGENE.
Is negative regulation of guanylate cyclase activity important in cancer?
While direct links are limited, cGMP signaling intersects with inflammatory and proliferative pathways such as CARD14-mTORC1, which are relevant to cancer biology.
What is the difference between guanylate cyclase and soluble guanylate cyclase?
Membrane guanylate cyclases like RetGC are regulated by GCAPs and RD3, while soluble guanylate cyclase is activated by nitric oxide and heme.
How does EDITGENE support research on negative regulation of guanylate cyclase activity?
EDITGENE provides custom CRISPR cell models, library screening, and bioinformatics to dissect the genes and mechanisms of GO:0031283.
Conclusion
GO:0031283 negative regulation of guanylate cyclase activity is a fundamental biological process that prevents excessive cGMP signaling. Its best-understood mechanism involves calcium-dependent inhibition of retinal guanylyl cyclase by GCAPs and RD3, with additional layers of control through protein-protein interactions and inflammatory crosstalk. Dysregulation of this process underlies retinal dystrophies, vascular disorders, and inflammatory skin diseases, making it a rich area for therapeutic targeting. By leveraging CRISPR knockout, point-mutation, knock-in, and overexpression models, researchers can precisely dissect the molecular players and translate findings into new treatments.
References
- 2. Dizhoor AM et al.. 2021. Regulation of retinal membrane guanylyl cyclase (RetGC) by negative calcium feedback and RD3 protein.. Pflugers Arch 473(9):1393-1410 PMID: 33537894
- 3. Su Y. 2014. Regulation of endothelial nitric oxide synthase activity by protein-protein interaction.. Curr Pharm Des 20(22):3514-20 PMID: 24180383
- 4. O'Sullivan PA et al.. 2024. CARD14 signalosome formation is associated with its endosomal relocation and mTORC1-induced keratinocyte proliferation.. Biochem J 481(18):1143-1171 PMID: 39145956
- 5. Avesani A et al.. 2021. Molecular properties of human guanylate cyclase-activating protein 2 (GCAP2) and its retinal dystrophy-associated variant G157R.. J Biol Chem 296:100619 PMID: 33812995
- 6. Pryymachuk G et al.. 2026. Regulation of Vascular Tone of Preglomerular Renal Vasculature by Caldesmon.. J Am Heart Assoc 15(2):e046679 PMID: 41553092
- 8. Ponka P. 1999. Cell biology of heme.. Am J Med Sci 318(4):241-56 PMID: 10522552
